Protease-activated receptor-4 and purinergic receptor P2Y12 dimerize, co-internalize, and activate Akt signaling via endosomal recruitment of (cid:2) -arrestin
暂无分享,去创建一个
[1] J. Trejo,et al. Challenges and Opportunities in Protease-Activated Receptor Drug Development. , 2017, Annual review of pharmacology and toxicology.
[2] J. Guay,et al. Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding , 2017, Science Translational Medicine.
[3] Thomas H. Smith,et al. Protease-activated Receptor-4 Signaling and Trafficking Is Regulated by the Clathrin Adaptor Protein Complex-2 Independent of β-Arrestins* , 2016, The Journal of Biological Chemistry.
[4] P. Gurbel,et al. Vorapaxar in the secondary prevention of atherothrombosis , 2015, Expert review of cardiovascular therapy.
[5] M. Cattaneo,et al. P2Y12 receptors: structure and function , 2015, Journal of thrombosis and haemostasis : JTH.
[6] Aasma A Khan,et al. The Physical Association of the P2Y12 Receptor with PAR4 Regulates Arrestin-Mediated Akt Activation , 2014, Molecular Pharmacology.
[7] A. Arachiche,et al. Protease-activated Receptor 1 (PAR1) and PAR4 Heterodimers Are Required for PAR1-enhanced Cleavage of PAR4 by α-Thrombin* , 2013, The Journal of Biological Chemistry.
[8] Thomas H. Smith,et al. Cofactoring and Dimerization of Proteinase-Activated Receptors , 2013, Pharmacological Reviews.
[9] J. Trejo,et al. Transactivation of the PAR1-PAR2 Heterodimer by Thrombin Elicits β-Arrestin-mediated Endosomal Signaling* , 2013, The Journal of Biological Chemistry.
[10] N. Hay,et al. ADP-Stimulated Activation of Akt During Integrin Outside-In Signaling Promotes Platelet Spreading by Inhibiting Glycogen Synthase Kinase-3&bgr; , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[11] S. Mundell,et al. Arrestin Scaffolds NHERF1 to the P2Y12 Receptor to Regulate Receptor Internalization* , 2012, The Journal of Biological Chemistry.
[12] Michael R Dores,et al. ALIX binds a YPX3L motif of the GPCR PAR1 and mediates ubiquitin-independent ESCRT-III/MVB sorting , 2012, The Journal of cell biology.
[13] Marc P. Bonaca,et al. Vorapaxar in the secondary prevention of atherothrombotic events. , 2012, The New England journal of medicine.
[14] D. Woulfe,et al. Arrestin-2 Differentially Regulates PAR4 and ADP Receptor Signaling in Platelets* , 2010, The Journal of Biological Chemistry.
[15] Meryem Köse,et al. High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors. , 2009, Journal of medicinal chemistry.
[16] Pascual Ferrara,et al. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[17] Eric Reiter,et al. GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling , 2006, Trends in Endocrinology & Metabolism.
[18] D. Siderovski,et al. Clathrin Adaptor AP2 Regulates Thrombin Receptor Constitutive Internalization and Endothelial Cell Resensitization , 2006, Molecular and Cellular Biology.
[19] C. Derian,et al. Blocking the Protease-Activated Receptor 1-4 Heterodimer in Platelet-Mediated Thrombosis , 2006, Circulation.
[20] S. Marley,et al. Targeting primary human leukaemia cells with RNA interference: Bcr‐Abl targeting inhibits myeloid progenitor self‐renewal in chronic myeloid leukaemia cells , 2005, British journal of haematology.
[21] R. Kriz,et al. N‐linked glycosylation of platelet P2Y12 ADP receptor is essential for signal transduction but not for ligand binding or cell surface expression , 2004, FEBS letters.
[22] Michel Bouvier,et al. Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patterns. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[23] A. Kuliopulos,et al. Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage. , 2003, The Biochemical journal.
[24] M. Freund,et al. Differential Involvement of the P2Y1 and P2Y12 Receptors in Platelet Procoagulant Activity , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[25] P. Conley,et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. , 2003, The Journal of clinical investigation.
[26] P. Nurden,et al. Role of ADP Receptor P2Y12 in Platelet Adhesion and Thrombus Formation in Flowing Blood , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[27] T. Kohout,et al. β-Arrestins Regulate Protease-activated Receptor-1 Desensitization but Not Internalization or Down-regulation* , 2002, The Journal of Biological Chemistry.
[28] S. Coughlin,et al. Protease-activated Receptors 1 and 4 Are Shut Off with Distinct Kinetics after Activation by Thrombin* , 2000, The Journal of Biological Chemistry.
[29] S. Coughlin,et al. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. , 1999, The Journal of clinical investigation.
[30] Robert V Farese,et al. A dual thrombin receptor system for platelet activation , 1998, Nature.
[31] Scott R. Presnell,et al. Cloning and characterization of human protease-activated receptor 4. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[32] Stephen S. G. Ferguson,et al. Synergistic Regulation of β2-Adrenergic Receptor Sequestration: Intracellular Complement of β-Adrenergic Receptor Kinase and β-Arrestin Determine Kinetics of Internalization , 1997 .
[33] V. Wheaton,et al. Domains specifying thrombin–receptor interaction , 1991, Nature.
[34] V. Wheaton,et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation , 1991, Cell.
[35] R. Abagyan,et al. A novel approach to quantify G-protein-coupled receptor dimerization equilibrium using bioluminescence resonance energy transfer. , 2013, Methods in molecular biology.